Detalles de la búsqueda
1.
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Br J Haematol
; 188(4): 501-510, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31588567
2.
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Blood
; 121(11): 1982-5, 2013 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23299315
3.
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Leukemia
; 34(12): 3286-3297, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32376855
4.
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.
Leuk Lymphoma
; 60(5): 1275-1282, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30380358
5.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Biol Blood Marrow Transplant
; 14(7): 795-8, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18541199
6.
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Clin Ther
; 40(7): 1193-1202.e1, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30007443
7.
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Leuk Lymphoma
; 48(12): 2330-7, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18067007
8.
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Clin Lymphoma Myeloma Leuk
; 17(9): 575-583.e2, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28886839
9.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Leuk Lymphoma
; 55(12): 2842-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24576165
10.
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Clin Cancer Res
; 19(6): 1534-46, 2013 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23357980
11.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood
; 111(3): 1101-9, 2008 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17989313
12.
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Br J Haematol
; 138(5): 640-3, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17686058
Resultados
1 -
12
de 12
1
Próxima >
>>